You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. The Nanopore-based Ion Selective Electrode Vial

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 400

    Project Summary An electrolyte panel is a blood test that measures the levels of electrolytes and carbon dioxide in your blood. Electrolytes are chemicals found naturally in the body, such as potassium, calcium, sodium, and are needed to keep the bodyandapos;s balance of fluids at the proper level and to maintain normal functions, such as heart rhythm, muscle contraction, and brain function. CO2 i ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practice

    SBC: MPROBE, INC.            Topic: NHLBI

    Project Summary Right ventricle (RV) dysfunction is a common and complex form of pediatric heart disease. It is also a common contributor to morbidity and mortality for patients with congenital heart diseases (CHD). Due to the complex geometry of the RV and its relative adaptability to changing physiologic conditions, RV dysfunction is poorly understood and difficult to characterize precisely and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Small Molecule Antagonists of PAR-2 for treatment of asthma

    SBC: PARMEDICS, INC.            Topic: NHLBI

    ABSTRACT: Current treatments for asthma largely are aimed at reducing exacerbations by directly treating airway inflammation. While successful in a subset of patients, asthma exacerbations remain a significant cause of morbidity and mortality and can result in airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering

    SBC: Fluid Discovery Inc            Topic: 400

    Project Summary Biocatalyst can be key tools in the synthesis of natural product-based pharmaceuticals and as powerful components of the pharmaceutical chemist’s drug modification kit. For example, the aromatic prenyltransferase NphB has utility in the synthesis of common prenylated compounds or derived backbones include cannabinoids, alpha acids, beta acids, phenylpropanoids, naphterpins, and m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Allosteric Drug Discovery using Quantum Cascade Laser based Anisotropic THz Microscope (QCL-ATM)

    SBC: LONGWAVE PHOTONICS LLC            Topic: 400

    Allosteric Drug Discovery using Quantum Cascade Laserbased Anisotropic THz Microscope (QCL-ATM) Proposal in Response to NIH/NIGMS STTR PA-20-265 This STTR will result in a commercially viable instrument that will enable critical research in allosteric drugs and protein dynamics. To date allosteric inhibitors are largely found serendipitously. Anisotropic THz microspectroscopy (ATM) uniquely measur ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Polymer use in Preservation of Tissue Perfusion to Address Sepsis

    SBC: PERFUSION MEDICAL LLC            Topic: 300

    Perfusion Medical is commercializing a novel pipeline product called PEG-20k IV Solution. The company believes this may be the first therapeutic to directly treat lethal complications of sepsis, and as such, support new thinking on the basic mechanisms of the disease. Sepsis or septic syndrome leads to a spectrum of illnesses and occurs at a frequency of 1.7 million people in the US each year and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Triagonist Peptide Therapeutics for Neuroprotection

    SBC: VELUM INC            Topic: 300

    Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, including chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one major cause that has been largely unnoticed but is increasingly recognized as a major concern is trau ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media

    SBC: OSSIUM HEALTH INC            Topic: 400

    ABSTRACT:The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of Goods (COGs). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of co ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government